The latest price target for Tourmaline Bio (NASDAQ:TRML) was reported by Wedbush on March 6, 2025. The analyst firm set a price target for $42.00 expecting TRML to rise to within 12 months (a possible 193.50% upside). 12 analyst firms have reported ratings in the last year.

The latest analyst rating for Tourmaline Bio (NASDAQ:TRML) was provided by Wedbush, and Tourmaline Bio initiated their outperform rating.

There is no last upgrade for Tourmaline Bio

There is no last downgrade for Tourmaline Bio.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tourmaline Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tourmaline Bio was filed on March 6, 2025 so you should expect the next rating to be made available sometime around March 6, 2026.

While ratings are subjective and will change, the latest Tourmaline Bio (TRML) rating was a initiated with a price target of $0.00 to $42.00. The current price Tourmaline Bio (TRML) is trading at is $14.31, which is within the analyst’s predicted range.